RxDoctor Payments Data

Christopher Berg, MD

Cardiovascular Disease · Fountain Valley, CANPI 1598296147

Payments from drug & device makers

$2,578in general payments, 2019–2025

Across 120 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$429
  • Novartis$393
  • Atricure, Inc.$263
  • Alnylam Pharmaceuticals Inc.$238
  • AstraZeneca$158
  • Biotronik Inc.$148
  • plus $948 from 22 others

What the payments were for

  • Food & beverage$2,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,578 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$182,442
Medicare patients
565
Services billed
1,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$209,039
EntrestoSacubitril/Valsartan59$58,304
XareltoRivaroxaban33$33,170
JardianceEmpagliflozin11$19,619
Metoprolol Succinate186$2,045
Atorvastatin Calcium127$1,541
Rosuvastatin Calcium74$1,541
Amlodipine Besylate253$992
Ezetimibe34$832
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide18$792
Losartan Potassium92$746
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$520
Metoprolol Tartrate71$444
Furosemide91$369
Potassium Chloride21$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$209,039177 claims
NovartisEntresto$393$58,30459 claims
Johnson & JohnsonXarelto$19$33,17033 claims
Boehringer IngelheimJardiance$429$19,61911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →